Artivion (AORT) Stock Overview
Manufactures, processes, and distributes medical devices and implantable human tissues worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AORT Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Artivion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.22 |
| 52 Week High | US$48.25 |
| 52 Week Low | US$19.16 |
| Beta | 1.25 |
| 1 Month Change | -4.14% |
| 3 Month Change | 22.43% |
| 1 Year Change | -38.55% |
| 3 Year Change | 64.51% |
| 5 Year Change | 1.57% |
| Change since IPO | 530.50% |
Recent News & Updates
Recent updates
Narrative Update • Jul 10
AORT: FDA Aortic Approval And Execution Progress Will Drive Future Upside
Artivion's updated analyst price target has moved from about $51.57 to $42.00, reflecting revised assumptions on growth, profitability, and future P/E as analysts incorporate a series of recent target cuts from firms covering the stock. Analyst Commentary Recent Street research on Artivion clusters around a series of price target cuts, along with one earlier addition to a conviction list.Seeking Alpha • Jun 30
Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion
Summary Artivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $150M U.S. TAM in acute aortic dissection. AMDS’s clinical data shows reduced mortality and major adverse events, with the elimination of DANE tears and durable benefit, supporting rapid, adoption-driven commercial scaling. AORT demonstrates double-digit revenue growth, margin expansion, and a shift to GAAP profitability, with EBITDA up 26% and gross margins nearing 65%. Valuation remains discounted at 2.4x forward sales, reflecting market skepticism on adoption speed and margin execution despite clear inflection toward profitability. Read the full article on Seeking Alpha
Narrative Update • Jun 26
AORT: Long Term Product Portfolio Expansion May Drive Future Upside Potential
Artivion's analyst price target has been reset lower from $58 to $48 as analysts factor in more moderate assumptions for revenue growth, profit margins and future P/E multiples, while applying a slightly higher discount rate. Analyst Commentary Despite the lower consolidated price target for Artivion, recent Street research includes several supportive signals that focus on execution, valuation and long term growth potential.New Narrative • May 09
Long Term Aortic Disease Treatments Will Reshape Earnings Power For This Business
Catalysts About Artivion Artivion focuses on medical devices and biologic products for treating aortic disease and heart valve disorders. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 29
AORT: Aortic Trial Approvals And Execution Progress Will Drive Future Upside
Analysts have modestly adjusted their price targets on Artivion, reflecting mixed recent research where one firm lowered its target by $3 while others turned more positive and added the stock to high-conviction lists. Analyst Commentary Recent research on Artivion points in different directions, with some analysts highlighting upside potential and others focusing on near term risks that affect how they frame valuation and execution.Narrative Update • Apr 15
AORT: Aortic Trial Data And Execution Progress Will Support Future Upside
Analysts have made a small upward adjustment to Artivion's fair value estimate, with the updated price target now at about $51.57, up from roughly $51.43. The revision reflects recent research that balances more constructive views with tempered expectations on margins and P/E assumptions.Narrative Update • Mar 31
AORT: Aortic Arch Trial Strength And Slightly Lower Risk Support Future Upside
Analysts have reduced their price target on Artivion by $3. This change reflects updated views on the company’s risk profile and long-term earnings potential.Narrative Update • Mar 17
AORT: Arch Trial Outcomes And Slightly Higher Discount Rate Will Support Upside
Analysts have trimmed their price target on Artivion by $3, reflecting a modestly higher discount rate and slightly updated long term P/E and margin assumptions, while keeping fair value expectations broadly in line with prior views. Analyst Commentary Recent research keeping fair value expectations broadly in line, while trimming the price target by $3, highlights a more nuanced view of Artivion.Narrative Update • Mar 03
AORT: Arch Trial Outcomes And Cleaned Up Assumptions Will Support Further Upside
Analysts have lowered their price target on Artivion by $3, reflecting updated assumptions around the discount rate, growth, and P/E. These changes keep the estimated fair value essentially unchanged at about $51.43.Analysis Article • Feb 19
We Think Artivion's (NYSE:AORT) Profit Is Only A Baseline For What They Can Achieve
Artivion, Inc.'s ( NYSE:AORT ) earnings announcement last week was disappointing for investors, despite the decent...Narrative Update • Feb 17
AORT: Arch Clinical Data And Execution Reset Will Support Further Upside
Analysts have trimmed their price target on Artivion by $0.29, reflecting slightly lower fair value estimates tied to modestly softer assumptions for revenue growth, profit margins, and future P/E multiple following recent research updates. Analyst Commentary Recent research has focused on how updated assumptions for revenue, margins, and P/E affect where Artivion might trade over time, with analysts weighing both upside levers and execution risks.Narrative Update • Feb 03
AORT: Beat And Raise Execution In Arch Therapies Should Drive Further Upside
Analysts have lifted their average price targets on Artivion into the low to mid US$50s, citing recent Q3 growth, updated 2025 to 2026 revenue projections around US$492m, and consistent commentary around the company’s fundamentals and margin profile as key supports for the higher valuation range. Analyst Commentary Bullish and more cautious analysts are reading the same data differently, but most are reacting to recent Q3 trends and updated revenue projections that now center around about US$492m for 2026, with Q3 year over year growth cited at about 16%.Narrative Update • Jan 19
AORT: Beat And Raise Execution In Stent Grafts Should Unlock Further Upside
Analysts have nudged their average price target on Artivion to about $51.71 per share, supported by recent target increases in the $40 to $55 range. They cite what they describe as strong Q3 growth, a beat and raise quarter, and steady fundamentals across the core and stent graft businesses.Narrative Update • Jan 05
AORT: Beat And Raise Execution In Stent Grafts Will Drive Continued Upside
Analysts have lifted their Artivion price targets into a roughly $40 to $55 range, citing Q3 year-over-year growth of about 16%, a revenue outlook that includes a projected $492m in 2026, and what they describe as strong fundamentals with a dependable base business and a complementary advanced stent graft division supporting EBITDA and margin performance. Analyst Commentary Recent Street research on Artivion clusters around a group of higher price targets in the low to mid US$40s and US$50s, with commentary focused on the pace of Q3 growth, revenue projections into 2026, and the contribution of the advanced stent graft business to EBITDA and margins.Narrative Update • Dec 15
AORT: Sustained Beat And Raise Pattern Will Drive Continued Upside Potential
Analysts have raised their blended price target for Artivion to about $51.71 per share, reflecting modestly lower discount assumptions and sustained confidence in double digit revenue growth and robust margins following recent beat and raise quarters, as well as upward target revisions across the Street to as high as $55. Analyst Commentary Bullish analysts emphasize that recent double digit top line expansion, including roughly mid teens revenue growth in the latest quarter, supports the view that Artivion can sustain an elevated growth algorithm and justify premium valuation multiples versus med tech peers.Narrative Update • Dec 01
AORT: Advancing Clinical Trials And Margin Outlook Will Support Continued Upside Potential
Analysts recently raised their price targets on Artivion shares, with increases ranging from $2 to $9. This reflects confidence in the company’s accelerating revenue growth, positive product updates, and robust margin outlook.Narrative Update • Nov 17
AORT: Momentum From Clinical Results And Margin Expansion Will Drive Upside
Artivion’s consensus analyst price target has increased significantly from approximately $45 to $52. Analysts cite accelerating revenue growth, robust third-quarter results, and improving profit margins as key drivers for their upward revisions.Narrative Update • Oct 31
AORT: Broader Physician Support And Clinical Advances Will Sustain Upside Amid Market Maturity
Analysts have raised their price targets for Artivion, with increases ranging from $38.80 to $47 per share. They cite the company’s strong core business performance, momentum in its high-growth aortic stent graft segment, and ongoing improvements in margins and profitability.Narrative Update • Oct 17
Aging Population And Global Approvals Will Advance Cardiac Devices
Artivion's analyst price target has been raised modestly from $44.54 to $45.26, as analysts point to ongoing strength in the company's core business, margin gains, and continued momentum in its Aortic stent graft segment. Analyst Commentary Recent analyst research on Artivion reflects a mix of optimism surrounding the company’s operational progress and a measured approach regarding its future outlook.Narrative Update • Oct 03
Aging Population And Global Approvals Will Advance Cardiac Devices
Analysts have raised their price target for Artivion by approximately $2.14 to $44.54. This change is based on constructive feedback from cardiac surgeons, positive incremental clinical updates, and ongoing confidence in the company’s growth prospects.Analysis Article • Sep 11
Artivion (NYSE:AORT) Might Have The Makings Of A Multi-Bagger
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Aug 12
Revenues Tell The Story For Artivion, Inc. (NYSE:AORT) As Its Stock Soars 37%
Despite an already strong run, Artivion, Inc. ( NYSE:AORT ) shares have been powering on, with a gain of 37% in the...Narrative Update • Aug 08
Aging Population And Global Approvals Will Advance Cardiac Devices
The significant upward revision in Artivion’s consensus price target reflects improved sentiment, underpinned by rising future P/E and net profit margin, resulting in a new fair value estimate of $38.00. What's in the News Raised 2025 revenue guidance to $435–$443 million, with expected constant currency growth of 12% to 14%.Analysis Article • Jul 10
Is Artivion (NYSE:AORT) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Narrative • May 28
Global Heart Valve Demand Will Expand Future Markets
Advances in medical technology, strong clinical evidence, and new product launches are expanding Artivion's market opportunities and enabling premium pricing for top-line growth.Analysis Article • May 09
Artivion, Inc.'s (NYSE:AORT) 29% Jump Shows Its Popularity With Investors
Those holding Artivion, Inc. ( NYSE:AORT ) shares would be relieved that the share price has rebounded 29% in the last...Analysis Article • May 06
Artivion, Inc.'s (NYSE:AORT) CEO Looks Like They Deserve Their Pay Packet
Key Insights Artivion to hold its Annual General Meeting on 13th of May CEO Pat Mackin's total compensation includes...Analysis Article • Apr 08
Here's Why Artivion (NYSE:AORT) Has A Meaningful Debt Burden
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Feb 27
Artivion, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
It's been a sad week for Artivion, Inc. ( NYSE:AORT ), who've watched their investment drop 13% to US$25.42 in the week...Analysis Article • Feb 13
Is Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)?
Artivion, Inc. ( NYSE:AORT ), is not the largest company out there, but it saw a decent share price growth of 12% on...Analysis Article • Jan 09
Why Investors Shouldn't Be Surprised By Artivion, Inc.'s (NYSE:AORT) P/S
It's not a stretch to say that Artivion, Inc.'s ( NYSE:AORT ) price-to-sales (or "P/S") ratio of 3.3x right now seems...Shareholder Returns
| AORT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.3% | -5.1% | -0.2% |
| 1Y | -38.5% | -17.5% | 14.8% |
Return vs Industry: AORT underperformed the US Medical Equipment industry which returned -19.2% over the past year.
Return vs Market: AORT underperformed the US Market which returned 15.5% over the past year.
Price Volatility
| AORT volatility | |
|---|---|
| AORT Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AORT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AORT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,800 | Pat Mackin | artivion.com |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries.
Artivion, Inc. Fundamentals Summary
| AORT fundamental statistics | |
|---|---|
| Market cap | US$1.23b |
| Earnings (TTM) | -US$3.19m |
| Revenue (TTM) | US$471.47m |
2.6x
P/S Ratio-385.3x
P/E RatioIs AORT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AORT income statement (TTM) | |
|---|---|
| Revenue | US$471.47m |
| Cost of Revenue | US$167.97m |
| Gross Profit | US$303.50m |
| Other Expenses | US$306.69m |
| Earnings | -US$3.19m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.065 |
| Gross Margin | 64.37% |
| Net Profit Margin | -0.68% |
| Debt/Equity Ratio | 81.6% |
How did AORT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 07:25 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Artivion, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| David Turkaly | Citizens JMP Securities, LLC |
| Daniel Stauder | Citizens JMP Securities, LLC |